GAINESVILLE, Fla. -- (BUSINESS WIRE) -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today that revenue for 2013 increased 6% to $237.1 million from $224.3 million in 2012. Diluted earnings per share for the year was $1.12 based on net income of $15.4 million, representing a 21% increase compared to net income of $12.7 million or $0.96 diluted earnings per share during 2012.
2013 Full Year Highlights and Segment Performance
2013 Fourth Quarter Highlights and Segment Performance
For the fourth quarter of 2013 revenue was $61.6 million, an increase of 4% over $59.3 million for the comparable period last year. Net income for the fourth quarter of 2013 increased 18% to $4.6 million, or $0.33 per diluted share, compared to $3.9 million, or $0.29 per diluted share, for the fourth quarter of 2012. Fourth quarter total and segment revenues were as follows:
Exactech Chairman and CEO Dr. Bill Petty said, “Overall, we are pleased with these results despite some international economic challenges. Our extremities segment drove the top line with a 26% gain to $65.5 million in 2013. Our domestic knee sales did well, and we were encouraged by improvements in our biologic and spine segment. Our 21% improvement in net income was particularly satisfying, as the people of Exactech worked effectively and efficiently to hold down costs and improve productivity. Looking ahead, our new product pipeline should provide fresh top line momentum in 2014. In addition, we expect our focus on increased productivity and lower costs will continue to contribute to net income growth.”
Exactech President David Petty said, “For the year 2013, U.S. sales increased 10% to $159.7 million, and international sales were down 2% to $77.4 million. During the fourth quarter, U.S. sales increased 9% to $41.8 million. International sales decreased 5% to $19.8 million.
“Our domestic knee product sales did well in the fourth quarter, providing us with good momentum going into 2014. We have increased the number of active trials of our new ExactechGPS® guided personalized surgery system, and that is already driving new knee sales to surgeons. Based on surgeon feedback, we are encouraged about the future impact of the system as a sales catalyst for our knee results. Our extremities business continues to be a growth leader both domestically and internationally. Our surgeon customers repeatedly report excellent patient outcomes, and that is playing an important role in propelling this segment.”
“Our hip business did well internationally but faced some challenges domestically after a particularly strong year in 2012. We are very pleased with improvements in our biologics and spine segment where we are seeing strong growth in the spine portion.”
Chief Financial Officer Jody Phillips said, “Operationally, we made significant improvements during 2013. Gross margins remained flat at 69% for 2013 and 2012 due to continued focus on maintaining cost reductions that offset the impact of the medical device excise tax. Total operating expenses for the year increased 4% to $140.1 million, and as a percentage of sales decreased to 59.1% from 59.8% for 2012. General and administrative expenses increased 5% for 2013 to $21.1 million from $20.1 million. Sales and marketing expenses increased 4% to $85.0 million, primarily due to variable selling expenses. Research and development expenses increased 6% to $17.8 million during 2013, as we continue to actively invest in our new product pipeline.”
Looking forward, Exactech released its initial 2014 revenue guidance of $246-$254 million and diluted EPS target of $1.18-$1.24. For the first quarter of 2014, the company anticipates revenues of $62-$64 million and diluted EPS of $0.28-$0.30. The foregoing statements regarding targets for the quarter and full year are forward-looking and actual results may differ materially. These are the company’s targets, not predictions of actual performance.
The financial statements are below.
The company will hold a conference call with CEO Dr. William Petty and key members of the management team on Thursday, February 20th at 10:00 a.m. Eastern Time. The call will cover Exactech’s fourth quarter and year-end 2013 results. Dr. Petty will open the conference call and a question-and-answer session will follow.
To participate in the call, dial 1-877-941-4774 any time after 9:50 a.m. Eastern on February 20th. International and local callers should dial 1-480-629-9760. A live webcast of the call will be available at http://www.hawkassociates.com/profile/exac.cfm or http://public.viavid.com/index.php?id=107717.
This call will be archived for approximately 90 days.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products, compliance costs and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
|EXACTECH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|December 31,||December 31,|
|Cash and cash equivalents||$||6,011||$||5,838|
|Accounts receivable, net of allowances of $993 and $1,012||59,109||48,073|
|Prepaid expenses and other assets, net||2,865||2,877|
|Income taxes receivable||1,331||502|
|Inventories – current||71,590||70,699|
|Deferred tax assets – current||1,653||2,229|
|Total current assets||142,559||130,218|
|PROPERTY AND EQUIPMENT:|
|Machinery and equipment||35,439||33,158|
|Furniture and fixtures||4,200||3,858|
|Projects in process||852||643|
|Total property and equipment||157,795||143,018|
|Net property and equipment||81,668||81,432|
|Deferred financing and deposits, net||870||866|
|Product licenses and designs, net||9,457||10,534|
|Patents and trademarks, net||2,005||2,217|
|Customer relationships, net||669||1,108|
|Total other assets||37,615||33,491|
|LIABILITIES AND SHAREHOLDERS’ EQUITY|
|Income taxes payable||39||2,188|
|Accrued expenses and other liabilities||10,974||11,726|
|Other current liabilities||250||250|
|Current portion of long-term debt||3,000||2,625|
|Total current liabilities||30,517||31,562|
|Deferred tax liabilities||4,200||3,186|
|Line of credit||10,732||12,197|
|Long-term debt, net of current portion||23,250||26,250|
|Other long-term liabilities||719||1,049|
|Total long-term liabilities||38,901||42,682|
|Additional paid-in capital||69,175||63,918|
|Accumulated other comprehensive loss||(3,902||)||(4,797||)|
|Total shareholders’ equity||192,424||170,897|
|TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY||$||261,842||$||245,141|
|EXACTECH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED STATEMENTS OF INCOME|
|(in thousands, except per share amounts)|
|Three Month Period||Twelve Month Periods|
|Ended December 31,||Ended December 31,|
|COST OF GOODS SOLD||19,228||18,043||73,019||68,731|
|Sales and marketing||21,718||21,478||84,999||81,979|
|General and administrative||5,348||5,192||21,149||20,139|
|Research and development||4,279||4,173||17,802||16,803|
|Depreciation and amortization||4,198||4,016||16,190||15,343|
|Total operating expenses||35,543||34,859||140,140||134,264|
|INCOME FROM OPERATIONS||6,807||6,352||23,929||21,342|
|OTHER INCOME (EXPENSE):|
|Foreign currency loss||(132||)||(284||)||(444||)||(90||)|
|Total other income (expense)||(431||)||(551||)||(1,521||)||(1,448||)|
|INCOME BEFORE INCOME TAXES||6,376||5,801||22,408||19,894|
|PROVISION FOR INCOME TAXES||1,781||1,921||7,036||7,153|
|BASIC EARNINGS PER SHARE||$||0.34||$||0.29||$||1.14||$||0.96|
|DILUTED EARNINGS PER SHARE||$||0.33||$||0.29||$||1.12||$||0.96|
|SHARES - BASIC||13,546||13,315||13,462||13,232|
|SHARES - DILUTED||13,844||13,383||13,683||13,317|